4//SEC Filing
V-Sciences Investments Pte Ltd 4
Accession 0000899243-18-009413
CIK 0001661998other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 1:33 PM ET
Size
22.8 KB
Accession
0000899243-18-009413
Insider Transaction Report
Form 4
TEMASEK HOLDINGS (PRIVATE) LTD
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2018-04-02−1,605,681→ 0 total(indirect: See footnotes)→ Common Stock (1,605,681 underlying) - Conversion
Series B Preferred Stock
2018-04-02−989,612→ 0 total(indirect: See footnotes)→ Common Stock (989,612 underlying) - Purchase
Common Stock
2018-04-02$16.00/sh+625,000$10,000,000→ 3,220,293 total(indirect: See footnote) - Conversion
Common Stock
2018-04-02+989,612→ 2,595,293 total(indirect: See footnote) - Conversion
Common Stock
2018-04-02+1,605,681→ 1,605,681 total(indirect: See footnote)
Fullerton Management Pte Ltd
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2018-04-02−1,605,681→ 0 total(indirect: See footnotes)→ Common Stock (1,605,681 underlying) - Conversion
Series B Preferred Stock
2018-04-02−989,612→ 0 total(indirect: See footnotes)→ Common Stock (989,612 underlying) - Conversion
Common Stock
2018-04-02+989,612→ 2,595,293 total(indirect: See footnote) - Purchase
Common Stock
2018-04-02$16.00/sh+625,000$10,000,000→ 3,220,293 total(indirect: See footnote) - Conversion
Common Stock
2018-04-02+1,605,681→ 1,605,681 total(indirect: See footnote)
Temasek Life Sciences Private LTD
10% Owner
Transactions
- Conversion
Common Stock
2018-04-02+1,605,681→ 1,605,681 total(indirect: See footnote) - Purchase
Common Stock
2018-04-02$16.00/sh+625,000$10,000,000→ 3,220,293 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2018-04-02−1,605,681→ 0 total(indirect: See footnotes)→ Common Stock (1,605,681 underlying) - Conversion
Common Stock
2018-04-02+989,612→ 2,595,293 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2018-04-02−989,612→ 0 total(indirect: See footnotes)→ Common Stock (989,612 underlying)
TLS Beta Pte. Ltd.
10% Owner
Transactions
- Conversion
Common Stock
2018-04-02+1,605,681→ 1,605,681 total(indirect: See footnote) - Purchase
Common Stock
2018-04-02$16.00/sh+625,000$10,000,000→ 3,220,293 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2018-04-02−989,612→ 0 total(indirect: See footnotes)→ Common Stock (989,612 underlying) - Conversion
Common Stock
2018-04-02+989,612→ 2,595,293 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2018-04-02−1,605,681→ 0 total(indirect: See footnotes)→ Common Stock (1,605,681 underlying)
V-Sciences Investments Pte Ltd
10% Owner
Transactions
- Conversion
Common Stock
2018-04-02+989,612→ 2,595,293 total(indirect: See footnote) - Conversion
Common Stock
2018-04-02+1,605,681→ 1,605,681 total(indirect: See footnote) - Purchase
Common Stock
2018-04-02$16.00/sh+625,000$10,000,000→ 3,220,293 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2018-04-02−1,605,681→ 0 total(indirect: See footnotes)→ Common Stock (1,605,681 underlying) - Conversion
Series B Preferred Stock
2018-04-02−989,612→ 0 total(indirect: See footnotes)→ Common Stock (989,612 underlying)
Footnotes (6)
- [F1]The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.
- [F2]The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.
- [F3]Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.
- [F4]Consists of 989,612 shares of Common Stock held of record by TLS Beta.
- [F5]Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.
- [F6]TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Documents
Issuer
Homology Medicines, Inc.
CIK 0001661998
Entity typeother
Related Parties
1- filerCIK 0001379350
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 1:33 PM ET
- Size
- 22.8 KB